Einloggen

Thematische Bibliographien / Interleukin-6 / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Interleukin-6.

Zeitschriftenartikel zum Thema „Interleukin-6“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 25. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Interleukin-6" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

&NA;. "Interleukin-3/interleukin-6." Reactions Weekly &NA;, no. 550 (1995): 11. http://dx.doi.org/10.2165/00128415-199505500-00035.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

&NA;. "Interleukin-6." Reactions Weekly &NA;, no. 570 (1995): 9. http://dx.doi.org/10.2165/00128415-199505700-00023.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Lotz, Martin. "Interleukin-6." Cancer Investigation 11, no. 6 (1993): 732–42. http://dx.doi.org/10.3109/07357909309046948.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

&NA;. "Interleukin 6." Inpharma Weekly &NA;, no. 877 (1993): 2. http://dx.doi.org/10.2165/00128413-199308770-00001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

&NA;. "Interleukin 6." Reactions Weekly &NA;, no. 505 (1994): 8. http://dx.doi.org/10.2165/00128415-199405050-00037.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

&NA;. "Interleukin 6." Reactions Weekly &NA;, no. 531 (1994): 8. http://dx.doi.org/10.2165/00128415-199405310-00027.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Song, Mingchen, and John A. Kellum. "Interleukin-6." Critical Care Medicine 33, Suppl (2005): S463—S465. http://dx.doi.org/10.1097/01.ccm.0000186784.62662.a1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

CASTELL, JOSé V., TILO ANDUS, DIETER KUNZ, and PETER C. HEINRICH. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (2008): 87–101. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24001.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

LEE, FRANK, CHOY-PIK CHIU, JANUSZ WIDEMAN, et al. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (2008): 215–29. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24015.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

CLARK, STEVEN C. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (2008): 438–43. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24036.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Olencki, Thomas, James Finke, and Ronald M. Bukowski. "Interleukin-6." Clinical Immunotherapeutics 2, no. 4 (1994): 278–94. http://dx.doi.org/10.1007/bf03258528.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Sin, Don D., and S. F. Paul Man. "Interleukin-6." Chest 133, no. 1 (2008): 4–6. http://dx.doi.org/10.1378/chest.07-2085.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Delk, Nikki A., and Mary C. Farach-Carson. "Interleukin-6." Autophagy 8, no. 4 (2012): 650–63. http://dx.doi.org/10.4161/auto.19226.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Matsuda, Tadashi, and Toshio Hirano. "Interleukin 6 (IL-6)." Biotherapy 2, no. 4 (1990): 363–73. http://dx.doi.org/10.1007/bf02170085.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Annisa, Yuanita Anggreini1 GontarAlamsyah Siregar*2 &. Leonardo Basa Dairi3. "ASSOCIATION BETWEEN INTERLEUKIN 6 SERUM LEVEL AND NON-ALCOHOLIC FATTY LIVER DISEASE." INTERNATIONAL JOURNAL OF RESEARCH SCIENCE & MANAGEMENT 6, no. 7 (2019): 11–16. https://doi.org/10.5281/zenodo.3342743.

Der volle Inhalt der Quelle

Annotation:

<strong>Background. </strong>Non-Alcoholic Fatty Liver Disease (NAFLD) emerged as a major health problem throughout the world and is increasing as the prevalence of obesity and diabetes continues to increase and is recognized as a major cause of liver disease-related morbidity and mortality. Adipokine is critically involved in healthy liver physiology and in the pathophysiology of acute and chronic liver disease as an intermediary for liver inflammation, liver cell death, cholestasis, and fibrosis. Interleukin-6 (IL-6) is one of adipokines widely studied recently. IL-6 showed improvement and p

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Rivera-Chavez, Fernando A., Dixie L. Peters-Hybki, Robert C. Barber, and Grant E. O'Keefe. "Interleukin-6 Promoter Haplotypes and Interleukin-6 Cytokine Responses." Shock 20, no. 3 (2003): 218–23. http://dx.doi.org/10.1097/00024382-200309000-00004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Ridker, Paul M. "Targeting Interleukin-1 and Interleukin-6." Journal of the American College of Cardiology 76, no. 15 (2020): 1774–76. http://dx.doi.org/10.1016/j.jacc.2020.08.052.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

NORTHEMANN, WOLFGANG, TODD A. BFUCIAK, MASAHIRA HATTORI, and GEORG H. FEY. "Rat Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (2008): 536–39. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24057.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Schneider, Kirsten, Reinhard Klaas, Bernd Kaspers, and Peter Staeheli. "Chicken interleukin-6." European Journal of Biochemistry 268, no. 15 (2001): 4200–4206. http://dx.doi.org/10.1046/j.1432-1327.2001.02334.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Tamura, T., N. Udagawa, N. Takahashi, et al. "Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6." Proceedings of the National Academy of Sciences 90, no. 24 (1993): 11924–28. http://dx.doi.org/10.1073/pnas.90.24.11924.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Ogawa, Michio, Kiyoshi Sakamoto, Seiji Mita, Takatoshi Ishiko, and Saburo Hisano. "INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR IN SURGICAL TRAUMA." Shock 4, Supplement (1995): 11. http://dx.doi.org/10.1097/00024382-199512001-00045.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

De Filippo, G., D. Rendina, F. Moccia, V. Rocco, and A. Campanozzi. "Interleukin-6, soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents." Journal of Endocrinological Investigation 38, no. 3 (2014): 339–43. http://dx.doi.org/10.1007/s40618-014-0176-4.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Oka, Masaaki, Hiroshi Kusanagi, Toshihiro Saeki, et al. "Interleukin-6 Production and Interleukin-6 Receptor Expression in Human Esophageal Cancer Cell Lines." Japanese Journal of Gastroenterological Surgery 26, no. 11 (1993): 2707. http://dx.doi.org/10.5833/jjgs.26.2707.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Prens, Errol P., Klazina Benne, Jozef van Damme, et al. "Interleukin-1 and Interleukin-6 in Psoriasis." Journal of Investigative Dermatology 95, no. 6 (1990): S121—S124. http://dx.doi.org/10.1111/1523-1747.ep12874991.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Bota, Rafaqat, and Mushtaq Ahmed. "The pathophysiological profile of interleukin-6 and anti-interleukin-6 antibody." El Mednifico Journal 1, no. 2 (2013): 51. http://dx.doi.org/10.18035/emj.v1i2.26.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Ridker, Paul M., and Manas Rane. "Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease." Circulation Research 128, no. 11 (2021): 1728–46. http://dx.doi.org/10.1161/circresaha.121.319077.

Der volle Inhalt der Quelle

Annotation:

IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of physiological functions traditionally associated with host defense, immune cell regulation, proliferation, and differentiation. Following recognition of innate immune pathways leading from the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome to IL-1 to IL-6 and on to the hepatically derived clinical biomarker CRP (C-reactive protein), an expanding literature has led to understanding of the proatherogenic role for IL-6 in cardiovascular disease and thus the potential for IL-6 inhibitio

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Jucker, M., H. Abts, W. Li, et al. "Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease." Blood 77, no. 11 (1991): 2413–18. http://dx.doi.org/10.1182/blood.v77.11.2413.2413.

Der volle Inhalt der Quelle

Annotation:

Abstract Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways. To examine whether IL-6 is possibly involved in the pathophysiology of Hodgkin's disease (HD), we analyzed the expression of IL-6 and IL-6 receptor mRNA and protein in cell lines and primary specimens from patients with HD. IL-6-specific tr

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Jucker, M., H. Abts, W. Li, et al. "Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease." Blood 77, no. 11 (1991): 2413–18. http://dx.doi.org/10.1182/blood.v77.11.2413.bloodjournal77112413.

Der volle Inhalt der Quelle

Annotation:

Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways. To examine whether IL-6 is possibly involved in the pathophysiology of Hodgkin's disease (HD), we analyzed the expression of IL-6 and IL-6 receptor mRNA and protein in cell lines and primary specimens from patients with HD. IL-6-specific transcripts

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Plenz, Gabriele, Heike Eschert, Michael Erren, et al. "The interleukin-6/interleukin-6-receptorsystem is activated in donor hearts." Journal of the American College of Cardiology 39, no. 9 (2002): 1508–12. http://dx.doi.org/10.1016/s0735-1097(02)01791-6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Nancey, Stéphane, Nadim Hamzaoui, Driffa Moussata, Ivan Graber, Jacques Bienvenu, and Bernard Flourie. "Serum Interleukin-6, Soluble Interleukin-6 Receptor and Crohn’s Disease Activity." Digestive Diseases and Sciences 53, no. 1 (2007): 242–47. http://dx.doi.org/10.1007/s10620-007-9849-6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Angelis, Pela, Simon Scharf, Alastair Mander, Frank Vajda, and Nicholas Christophidis. "Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease." Neuroscience Letters 244, no. 2 (1998): 106–8. http://dx.doi.org/10.1016/s0304-3940(98)00136-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Rezai, Ali R., Ahmad Rezai, Otoniel Mart�nez-Maza, Meta Vander-Meyden, and Martin H. Weiss. "Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors." Journal of Neuro-Oncology 19, no. 2 (1994): 131–35. http://dx.doi.org/10.1007/bf01306454.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

MONTERO-JULIAN, F. A., E. GAUTHEROT, J. WIJDENES, B. KLEIN, and H. BRAILLY. "Pharmacokinetics of Interleukin-6 During Therapy with Anti-Interleukin-6 Monoclonal Antibodies: Enhanced Clearance of Interleukin-6 by a Combination of Three Anti-Interleukin-6 Antibodies." Journal of Interferon Research 14, no. 5 (1994): 301–2. http://dx.doi.org/10.1089/jir.1994.14.301.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

KENIS, G., C. TEUNISSEN, R. DEJONGH, E. BOSMANS, H. STEINBUSCH, and M. MAES. "STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM." Cytokine 19, no. 5 (2002): 228–35. http://dx.doi.org/10.1016/s1043-4666(02)91961-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Kenis, Gunter, Charlotte Teunissen, Raf De Jongh, Eugène Bosmans, Harry Steinbusch, and Michael Maes. "STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM." Cytokine 19, no. 5 (2002): 228–35. http://dx.doi.org/10.1006/cyto.2002.1961.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

HIRANO, TOSHIO. "Interleukin 6 (IL-6) and disease." Japanese Journal of Clinical Immunology 13, no. 5 (1990): 444–45. http://dx.doi.org/10.2177/jsci.13.444.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Van Wagoner, N. J., and E. N. Benveniste. "Interleukin-6 regulation in human astrocytes: Synergy between TNF-alpha, interleukin-6, and the soluble-interleukin-6 receptor-alpha." Journal of Neuroimmunology 90, no. 1 (1998): 53. http://dx.doi.org/10.1016/s0165-5728(98)91497-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Abasova, Dunya, Sevda Kazimova, Nazrin Macidova, Telli Shirinova, and Shalala Babayeva. "STUDY OF STOKIN STATUS IN PATIENTS WITH TOXOPLASMOSIS." Annali d'Italia 50 (December 26, 2023): 17–19. https://doi.org/10.5281/zenodo.10432472.

Der volle Inhalt der Quelle

Annotation:

The problem of opportunistic infections is becoming an urgent problem of modern times is becoming, which is a constant increase in the number of people infected with HIV, it is related to the increase in aggressive treatment methods of oncopathologies. This infections Pathogens that can normally cause disease in healthy individuals caused by Up to 20 typical causative agents of opportunistic infections are known, and in modern infectious diseases this list is constantly growing. without symptoms: 60% - cytomegalovirus, 90% - first and second type herpavirus, 30% are toxoplasma c

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Sajjad, Kathem Ashour, Abd Jabbar Al-Ammar Haider, and Hamza Sharif Yasmine. "Interleukin-6 Biomarker as Possible Predicator of Preeclampsia." Biomedicine and Chemical Sciences, no. 4 (September 30, 2022): 306–11. https://doi.org/10.48112/bcs.v1i4.303.

Der volle Inhalt der Quelle

Annotation:

Preeclampsia (PE) is a serious illness that can harm both mothers and unborn children and may even be fatal. It contributes significantly to maternal fatalities in underdeveloped countries. PE, which affects 2%–3% of women who are pregnant after 20 weeks of pregnancy, is marked by proteinuria and hypertension. PE is a significant condition that plays a significant role in maternal fatalities in underdeveloped countries and is a significant cause of death for both mothers and newborns. Each year, around 60,000 maternal fatalities occur in the world. Serum interleukin-6 (IL-6) was measured

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Hoejberg, Lise, Lars Bastholt, and Henrik Schmidt. "Interleukin-6 and melanoma." Melanoma Research 22, no. 5 (2012): 327–33. http://dx.doi.org/10.1097/cmr.0b013e3283543d72.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Rose-John, Stefan. "Interleukin-6 Family Cytokines." Cold Spring Harbor Perspectives in Biology 10, no. 2 (2017): a028415. http://dx.doi.org/10.1101/cshperspect.a028415.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Tanaka, Toshio, Masashi Narazaki, and Tadamitsu Kishimoto. "Interleukin (IL-6) Immunotherapy." Cold Spring Harbor Perspectives in Biology 10, no. 8 (2017): a028456. http://dx.doi.org/10.1101/cshperspect.a028456.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Suzuki, Kenshi, Akiko Miyashita, Yasuyuki Inoue, et al. "Interleukin-6-Producing Pheochromocytoma." Acta Haematologica 85, no. 4 (1991): 217–19. http://dx.doi.org/10.1159/000204897.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Kerr, Ron, David Stirling, and Christopher A. Ludlam. "Interleukin 6 and Haemostasis." British Journal of Haematology 115, no. 1 (2001): 3–12. http://dx.doi.org/10.1046/j.1365-2141.2001.03061.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Nagila, Amar, Khem Raj Paudel, and Bijay Subedi. "Interleukin-6 in Hypothyroidism." Journal of Manmohan Memorial Institute of Health Sciences 9, no. 2 (2024): 27–29. http://dx.doi.org/10.3126/jmmihs.v9i2.71838.

Der volle Inhalt der Quelle

Annotation:

Background: Hypothyroidism means that the thyroid gland can’t produce enough thyroid hormones. Interleukin 6 (IL-6) a cytokine of innate immunity is a soluble mediator with a pleotropic effect on inflammation. Interleukin 6 test is helpful to study the hypothyroid status and to assess the adverse effects of hypothyroidism, was not studied in a tertiary care center in Pokhara, Nepal. The aim of this study is to determine the levels of interleukin 6 and to correlate with hypothyroidism. Methodology: This was a hospital based cross-sectional study on 100 hypothyroid patients where samples were co

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Sehgal, Pravinkumar B. "Interleukin-6: Molecular Pathophysiology." Journal of Investigative Dermatology 94, no. 6 (1990): s2—s6. http://dx.doi.org/10.1111/1523-1747.ep12874963.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Van Snick, Jacques. "Interleukin-6: An Overview." Annual Review of Immunology 8, no. 1 (1990): 253–78. http://dx.doi.org/10.1146/annurev.iy.08.040190.001345.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Pedersen, Bente Klarlund, Adam Steensberg, and Peter Schjerling. "Exercise and interleukin-6." Current Opinion in Hematology 8, no. 3 (2001): 137–41. http://dx.doi.org/10.1097/00062752-200105000-00002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Patarca, Roberto, and Mary Ann Fletcher. "Interleukin-6 and Disease." Journal of Chronic Fatigue Syndrome 4, no. 1 (1998): 53–69. http://dx.doi.org/10.1300/j092v04n01_07.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

SEHGAL, PRAVIN B., LING WANG, RAVI RAYANADE, HENG PAN, and LOLA MARGULIES. "Interleukin-6-Type Cytokinesa." Annals of the New York Academy of Sciences 762, no. 1 (2006): 1–14. http://dx.doi.org/10.1111/j.1749-6632.1995.tb32309.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!